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 Three independent mutations in the gene coding elongase
of very long chain fatty acids-4 (ELOVL4) have been shown
to cause Stargardt disease-3 (STGD3), a juvenile-onset, auto-
somal dominant macular degeneration [1-4]. This hereditary
disease is characterized by accumulation of lipofuscin and
gradual loss of central vision [5,6]. ELOVL4 is homologous
with five other enzymes known to elongate very long chain
fatty acids, but its substrate/product specificity and physiologi-
cal role are currently unknown. All three human STGD3 patho-
genic mutations lead to a truncated ELOVL4 protein deprived
of its C-terminal sequence containing a signal for retention in
the endoplasmic reticulum (ER) [1].
In mammals, all fatty acids longer than 16 carbon atoms
are either derived from dietary sources or are synthesized in
the ER [7]. The synthesis requires four enzymes to catalyze
four consecutive reactions: condensation of a fatty acyl-CoA
with malonyl-CoA, reduction of the resulting 3-ketoacyl-CoA,
dehydration of the 3-hydroxyacyl-CoA to 2,3-enoylacyl-CoA
followed by a final reduction step. The first and rate limiting
step [7] is catalyzed by elongase of very long chain fatty acids
(Elovl). The six known mammalian elongases exhibit differ-
ential tissue expression [8]. In addition to Elovl 1-6, DNA
sequence in Genbank (Genbank accesion number BC005602)
suggests that there is a seventh member of the Elovl family
which has similarity to Elovl1.
Three of the characterized enzymes elongate saturated
fatty acids: Elovl1 synthesizes fatty acids with 26 carbon at-
oms (C26), Elovl3 elongates C16-C22 substrates and Elovl6
extends C12-C16 fatty acids. Polyunsaturated fatty acids, C20-
C22, and C18-C20, are elongated by Elovl2 and Elovl5, re-
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Purpose: Autosomal dominant Stargardt disease-3 (STGD3) is caused by mutations in elongase of very long chain fatty
acids-4 (ELOVL4). The goal of this study was to generate and characterize heterozygous and homozygous knockin-mice
that carry a human STGD3 pathogenic mutation in the mouse Elovl4 gene.
Methods: Recombinant Stgd3-knockin mice were generated using a DNA construct which introduced a pathogenic five-
base pair deletion and two point mutations in exon 6 of the Elovl4 gene. Stgd3-mouse genotypes were confirmed by
Southern blot analysis and expression of wild-type (wt) and mutated Elovl4 mRNAs assayed by nuclease protection
assay. The retinal phenotype of heterozygous Stgd3 mice was characterized by morphological studies, elecroretinographic
(ERG) analysis and assay of lipofuscin accumulation. Homozygous Stgd3 mice were examined for both retinal and gross
morphology. They were also analyzed for skin morphology and skin barrier function, and for epidermal lipid content
using high performance liquid chromatography (HPLC) combined with mass spectrometry (MS).
Results: The Stgd3 allele codes for a truncated mouse Elovl4 protein, which also contains the same aberrant 8-amino acid
C-terminus encoded by the human pathogenic STGD3 allele. Heterozygous Stgd3 mice expressed equal amounts of both
wt and mutant Elovl4 mRNAs in the retina, showed no significant changes in retinal morphology, but did show accumu-
lation of lipofuscin and reduced visual function. Homozygous Stgd3 mice were born with an expected Mendelian fre-
quency, without any initial gross anatomical or behavioral abnormalities. By 6-12 h postpartum, they became dehydrated
and died. A skin permeability assay detected a defect in epidermal barrier function. Homozygous mutant epidermis ex-
pressed a normal content of mutated Elovl4 mRNA and contained all four epidermal cellular layers. HPLC/MS analysis of
epidermal lipids revealed the presence of all barrier lipids with the exception of the complete absence of acylceramides,
the critical lipids for barrier function of the skin.
Conclusions: The generated Stgd3-knockin mice are a genetic model of human STGD3 and reproduce features of the
human disease: accumulation of lipofuscin and reduced visual functions. Homozygous Stgd3 mice showed a complete
absence of acylceramides from the epidermis. Their absence suggests a role for Elovl4 in acylceramide synthesis, and in
particular, a role in the synthesis of the unique very long chain C30-C40 fatty acids present in skin acylceramides.
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258spectively. Despite the use of similar approaches to those which
led to successful identification of the substrates for the five
characterized elongases, the substrate/product specificity of
Elovl4 still remains unknown [9].
A role for ELOVL4 in the synthesis of docosahexaenoic
acid (DHA, 22:6n-3), which represents approximately 50%
of the fatty acids in retinal outer segment phospholipids [10],
has been proposed [1]. DHA is synthesized from dietary es-
sential linolenic acid (18:3n-3) in a series of three elongation
steps [11], but to date no evidence has been presented to de-
fine a role for ELOVL4 in this pathway. In addition to DHA,
the retina also contains C24-C36 polyenoic fatty acids, present
in photoreceptor outer segment phosphatidylcholines [12],
which are synthesized from eicosapentaenoic acid (20:5n-3)
[13]. Reduced retinal synthesis of very long chain fatty acids,
such as DHA as well as C24-C36 polyenoic fatty acids, as a
result of a mutated ELOVL4 could play a role in the patho-
genesis of STGD3.
Both cell biology and animal model studies have been
performed to try to understand the function of Elovl4. In vitro
expression of an ELOVL4 transgene with a five-bp STGD3
deletion showed translocation of the mutated protein out of
the ER [14,15]. When co-expressed, the mutant protein bound
wt Elovl4 protein and carried it from the ER [16-18]. These
findings suggest that the STGD3 mutation has a dominant
negative effect which might lead to reduction in the levels of
the currently unidentified ELOVL4 lipid products.
Results from studies in three different animal models of
STGD3 have been reported recently. Studies in transgenic mice
expressing the mutant STGD3 form of ELOVL4 in photore-
ceptors showed lipofuscin accumulation, retinal degeneration
and reduced ERG signals [19], all features of human STGD3.
In a second study, to address the physiological role of Elovl4,
Elovl4-knockout mice were generated [20]. Retinas of het-
erozygous knockout mice demonstrated essentially normal
retinal ERG function and minimal morphological abnormali-
ties. The retinas of these mice had, however, a reduced con-
tent of several mono-unsaturated C16-C24 fatty acids. Ho-
mozygous knockout pups could not be obtained in this study.
The third model reported is a heterozygous knock-in that in-
troduced the five-bp STGD3 deletion in the mouse Elovl4 gene
[21]. At an age of 7-10 months, these mice had increased ERG
signals, shortened photoreceptor outer segments without any
loss of cell bodies, reduced Elovl4 mRNA levels, and a re-
duced content of several C18-C24 mono-, penta- and hexa-
unsaturated fatty acids. No information about homozygous
knockin mice was reported for this last study.
We have also generated a genetic knockin mouse model
of STGD3. However, we chose to generate gene-knockin mice
that carry not only the human 5-bp STGD3 pathogenic dele-
tion in exon 6 of the mouse Elovl4 gene but also two down-
stream single nucleotide substitutions. This design resulted in
generation of an Stgd3 allele that coded for a truncated mouse
Elovl4 protein which also contained an aberrant 8-amino acid
C-terminus identical to that encoded by the human pathogenic
STGD3 allele [1]. Our heterozygous Stgd3 mice reproduced
retinal features of the human disease, lipofuscin accumula-
tion and reduced vision, thus validating these animals as a
mouse model suitable for studying the biochemical basis of
STGD3 pathogenesis. One hypothetical STGD3 pathogenic
mechanism is a “loss of function” mechanism resulting in de-
ficiency of selected lipids, the putative Elovl4 products, in
Elovl4-expressing tissues. Support for this mechanism is pro-
vided by the results of our analysis of epidermal lipids in neo-
natal homozygous Stgd3 mice which revealed a complete ab-
sence of acylceramides, a unique group of compound lipids
containing C30-C40 fatty acids.
METHODS
Generation of Stgd3-gene knockin mice: The targeting con-
struct contained 4.2-kb of 5'-recombination target, a 1.6-kb
loxP-flanked Neo cassette, 2.6-kb of genomic DNA contain-
ing the 2.1-kb Elovl4 exon 6 sequence with the human STGD3
mutation, and 3.1-kb of 3'-recombination target (Figure 1B).
Mouse DNA sequences were amplified using 128SvEv mouse
DNA and the High Fidelity PCR System (Stratagene, La Jolla,
CA) and cloned, together with the Neo cassette, into a PCR-
XL-TOPO vector (Invitrogen, Carlsbad, CA). The unique re-
striction sites (SphI, AsiSI and MfeI, Figure 1B) used for clon-
ing were incorporated in the sequence of PCR primers. Prior
to targeting construct assembly, the PCR product with the
Elovl4 exon 6 sequence was mutated using internal PCR prim-
ers containing the human STGD3 mutation. The final 15-kb
targeting construct was linearized using the vector-located
SmaI site, and electroporated into 129SvEv embryonic stem
cells, yielding 360 clones that survived G418 selection. South-
ern blot analysis of stem cell DNA digests detected three clones
with homologous recombination. One of these, clone number
2F4, was injected into C57BL/6 blastocysts, resulting in the
birth of 33 high-percentage male chimeras by coat color. Eight
chimeric males were bred with 129SvEv females. PCR
genotyping of their F1 offspring revealed that six males trans-
ferred the recombined allele with the Neo cassette to the next
generation of Neo mice. To remove the loxP-flanked Neo cas-
sette and obtain Stgd3 mice, the progeny of male number 3
were bred with Cre-transgenic mice, strain 129S1-Hprt™
(Cre)Mnn/J (Jackson Laboratory, Bar Harbor, ME).
Electroporation, culture of embryonic stem cells and gen-
eration of chimeric mice were all done by The UT Southwest-
ern Transgenic Technology Center. Mice were housed in The
UT Southwestern Animal Resource Center under a 12 h light/
12 h dark cycle and fed ad libidum a standard chow diet. All
experiments were approved by the Institutional Animal Care
and Use Committee of The UT Southwestern Medical Center,
Dallas, TX.
Southern blot analysis of knockin mice:  Tail DNA samples
were digested with NsiI or Bpu10I (New England Biolabs,
Beverly, MA), separated on an agarose gel, transferred to
Hybond N+ membrane (GE Healthcare, Piscataway, NJ), and
subjected to Southern blot analysis using P32-labeled DNA
probes: a 453-bp 5'-external probe, a 284-bp Neo probe, or a
1.2-kb 3'-internal probe (Figure 1B).
Polymerase chain reaction genotyping of mice:  After
founder mice were characterized by Southern blot analysis,
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259further genotyping of their progenies was performed by PCR
using tail DNA. The wt and Stgd3-mutant sequences (with or
without the Neo cassette) were detected by PCR reactions run
for 30 cycles of 15 s at 94 °C, 15 s at 60 °C, and 30 s at 72 °C
using the sense primer 5'-GCA ATC ACT AGA ATG CCC
TTG CTG AGC AGG TG-3' for both reactions, and antisense
primer 5'-GGC TCA TTG TAT GTC CGA GTG TAG AAG
TTG-3' for wt sequence and 5'-GCT CTT TGT ATG TCC GAG
TGT AGG AGG A-3' for mutant sequence. Products of 332
and 327 bp were obtained for the wt and mutant sequences,
respectively. The presence of a Stgd3-allele with a Neo dele-
tion was detected as an 84-bp PCR product following 35 cycles
of 15 s at 94 °C, 15 s at 65 °C, and 15 s at 72 °C using sense
primer 5'-CGC GCC ATC GAT GGA TCC GGT ACC ATA
ACT TCG-3' and antisense primer 5'-TGG TTT CCC CAA
GGC AGT GCG ATC GCA TAA CTT CG-3'. The Cre
transgene was detected by the presence of a 102-bp PCR prod-
uct following 35 cycles of 30 s at 94 °C, 15 s at 56 °C, and 15
s at 72 °C, using primers designed by The Jackson Labora-
tory: sense 5'-GTG AAA CAG CAT TGC TGT CAC TT-3'
and antisense 5'-GCG GTC TGG CAG TAA AAA CTA TC-
3'.
Nuclease protection assay:  Total RNA was extracted from
individual samples of mouse tissues using RNA-Stat60 reagent
(Tel-Test, Inc., Friendswood, TX) according to the
manufacturer’s protocol. RNA samples were hybridized to an
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Figure 1. Gene-targeting strategy for generation of Stgd3-gene knockin mice.  A: Partial nucleotide sequence from exon 6, and the encoded
amino acids (capital letters), of the wt (Elovl4) and mutant (Stgd3) alleles. Shown are the mutations introduced into the Elovl4 sequence prior
to assembly of the targeting construct. Five nucleotide base pairs, corresponding to those absent in Stargardt-3 patients, were deleted (del).
Two point mutations (the altered and substituted nucleotides are shown in blue) were introduced in the sequence downstream of the deletion
to generate a new C-terminal sequence that is identical to that found in STGD3 patients. B: Schematic maps of a portion of the Elovl4 allele
encompassing exons 4, 5, and 6, the targeting construct, recombinant allele and the final Stgd3 allele. Restriction sites used for cloning and for
Southern blot verification of recombination and deletion events, as well as the location of the Southern probes are included. Mutations in exon
6 are shown schematically as a shaded box, within which the new Bpu10I restriction site introduced during sequence manipulation is shown.
Homologous recombination of the 11.5-kb targeting construct generates a recombinant allele containing exon 6 with the Stgd3 mutation, a
neomycin selection cassette (Neo) flanked by lox P sites (L), and 4.2 kb and 3.1kb of 5'- and 3'-targeting sequence, respectively. Breeding of
recombinant Neo/wt mice with Cre-transgenic mice leads to Cre-mediated deletion of the Neo cassette and generation of the mice carrying the
final Stgd3 allele.
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antisense [α-32P]UMP-labeled 322-nucleotide (N) RNA probe
containing 182-N sequence of mouse Elovl4 mRNA (nucle-
otides number 840-659). After hybridization and S1 nuclease
digestion, protected fragments were analyzed by electrophore-
sis on 8% polyacrylamide gels containing 8 M urea, as de-
scribed previously [22]. The 182-N riboprobe fragment pro-
tected by Elovl4 (wt) mRNA, and two riboprobe fragments
(containing 126 Ns and 51 Ns) protected by Stgd3 (mutant)
mRNA were quantified on a Typhoon 9410 phosphoimager
(Amersham Biosciences Corporation, Piscataway, NJ) and
normalized for their content of radioactive UMP nucleotide.
Analysis of A2E and its precursors:  Mice were euthanized
using halothane in the middle of the light phase of the day/
night cycle. Eyecups were collected, extracted with chloro-
form and isolated retinal fluorophores analyzed as previously
described [23].
Electroretinogram analysis:  Mice were dark adapted
overnight with eyes dilated by topical application of 0.25%
Isopto Hyoscine. Next day, after repeated eye dilation, mice
were anesthetized by intraperitoneal injection of a saline so-
lution containing Ketamine (200 mg/kg body weight) and
Xylazine (10 mg/kg body weight). A Burian-Allen lens placed
on one cornea was referenced to a needle electrode in the scalp.
A needle electrode in the tail served as ground. To stabilize
body temperature during testing, mice were placed between
two heating pads. Rod and cone signals were recorded fol-
lowing ISCEV standard protocol. Signals were amplified
(Tektronix AM502 differential amplifier; x10,000; 3 dB down
at 2 and 10,000 Hz), digitized (sampling rate=1.25 to 5 kHz)
and averaged on a personal computer. Two different flash
stimulators were utilized. A Grass photostimulator provided
short-wavelength 10 msec flashes (Wratten 47A: max=470
nm, half-bandwidth=55 nm) from-3.88-1.27 log scot td-s. A
Novatron flash unit produced high-intensity 1.3 msec flashes
from 0.9-3.65 log scot td-s. A steady background (3.2 log ph
td) was used to isolate cone responses.
Histology of mouse eyecups and skin:  Mice were
euthanized using halothane. Eyecups were collected from adult
mice, and the head and skin from the dorsal trunk of new-
born mice. Tissue samples were fixed overnight in phosphate
buffered saline (PBS), pH 7.4, containing 4% formaldehyde.
Then, they were dehydrated, paraffin embedded, and sectioned
prior to staining with hematoxylin and eosin, using established
procedures [24].
Skin permeability assay:  New-born mice were euthanized
using halothane. Tails were collected for PCR genotyping and
bodies were tested for skin barrier function according to [25]
with one modification. Instead of a methanol wash, bodies
were rinsed in PBS. Then, they were immersed in a PBS buffer
containing 0.1% toluidine blue for 2-4 h at room temperature,
washed briefly with PBS and photographed.
HPLC/mass spectrometric analysis of epidermal lipids:
Excised dorsal skin of new-born mice was immersed in PBS
containing 10 mM EDTA at 37 °C for 45 min to separate the
epidermis from the dermis as described previously [26]. Epi-
dermal samples were snap frozen in liquid nitrogen and stored
at -80 °C until analyzed. Samples were homogenized in 1.5
ml of a chloroform/methanol mixture (1:2 v/v) using a glass
homogenizer, extracted overnight at 37 °C and centrifuged in
a glass tube. The pellet was re-extracted overnight with 1.5 ml
of a chloroform/methanol mixture (2:1 v/v) and centrifuged
as before. The combined extracts were evaporated under ar-
gon and dissolved in chloroform/methanol (1:1 v/v) at a con-
centration of 0.1-0.5 mg/mL and fractionated by high perfor-
mance liquid chromatography (HPLC) as described by [27].
Mass spectrometric (MS) analysis was performed using a LCQ
Deca XP Max MSn spectrometer (Thermo Electron Corpora-
tion, San Jose, CA) equipped with an atmospheric pressure
chemical ionization ion source. Full MS spectra between m/z
values of 100 and 2000 were collected in both the negative
and positive ion modes. For positive ion mode analyses, the
following conditions were applied: source voltage = 3.75 kV,
source current=5 A, vaporizer temperature=375 °C, sheath gas
(N2) flow=25 arbitrary units, auxiliary/sweep gas flow=4 ar-
bitrary units, capillary voltage=12V, capillary temperature=300
°C. In negative mode experiments, the following conditions
were used: source voltage=1.25 kV, source current=4.5 A,
vaporizer temperature = 375 °C, sheath gas (N2) flow=25 ar-
bitrary units, auxiliary/sweep gas flow=4 arbitrary units, cap-
illary voltage = -15V, capillary temperature=300 °C.
Structural analysis of ceramides was performed using di-
rect infusion of samples at a flow rate of 5-10 µl/min. Parent
ions were subjected to collision induced dissociation by he-
lium at 33-45% relative energy and resulting spectra accumu-
lated for 1-2 min. MS experimental parameters were as de-
scribed before.
RESULTS
Generation of Stgd3-gene knockin mice: An Elovl4-targeting
construct was generated in which exon 6 sequence was mu-
tated to introduce a human disease-associated deletion, with
an exact replication of the new C-terminal peptide sequence
of the truncated human protein (Figure 1A). The human patho-
genic 5-bp deletion in ELOVL4 causes a frame shift which
both removes an ER retention signal and truncates the 49-
amino acid C-terminus to an aberrant 8-amino acid C-termi-
nus (LHSDIQRA). To achieve this same truncated aberrant
C-terminus in Stgd3-gene knockin mice, two point substitu-
tions were introduced in the nucleotide sequence downstream
of the deletion site (Figure 1A). Without these additional point
mutations the truncated C-terminus would be shorter by only
six amino acids (LHSDIQ). The final construct was then used
to generate Stgd3 mice (Figure 1B).
Southern blot analysis of genomic DNA confirmed ho-
mologous recombination of the targeting construct in knockin
mice, the presence of the Neo-cassette used for ES cell clone
selection in Neo mice and its absence in the final Stgd3 mice
(Figure 2). The mutations engineered into the Elovl4 gene in-
troduced a BpuI restriction site into exon 6. The resulting de-
tection of a new hybridization band following Southern blot
analysis of BpuI-digested tail DNA further confirmed the pres-
ence of the Stgd3 allele in Stgd3 mice (Figure 2C). The Stgd3
allele codes for a shortened Elovl4 protein that contains a wt
N-terminal sequence of 263 amino acids and a C-terminus
261downstream of the mutation containing only eight amino ac-
ids. In summary, analysis of genomic DNA validated our Stgd3
mice as a genetic animal model that carries the human patho-
genic STGD3 mutation in the mouse Elovl4 gene.
Heterozygous Stgd3 mice reproduce retinal features of
human STGD3:  The heterozygous Stgd3 animals displayed
no obvious gross morphological or behavioral alterations when
compared to their wt littermates. Since STGD3 is a dominant
retinal disease, we examined the eyes of our generated mutant
mice for alterations. First, the mRNA levels derived from both
the wt and Stgd3 alleles were measured by an S1-nuclease
protection assay that discriminated between and allowed quan-
tification of both wt and mutant Elovl4 mRNAs. In contrast to
some retinal mRNAs, Elovl4 mRNA levels did not undergo
diurnal changes in mouse retinas (Figure 3A). Also, the level
of wt Elovl4 mRNA in heterozygous Stgd3 retinas was not
affected by the Stgd3 mutant allele, since it was found to be
half of the Elovl4 mRNA level that was present in wt retinas
(Figure 3B). This shows a lack of any regulatory mechanisms
that induce over-expression from the wt Elovl4 allele to com-
pensate for the presence of the mutated allele. The Stgd3 mu-
tation also had no effect on stability of mutated Elovl4 mRNA
since the retinas of heterozygous Stgd3 mice expressed equal
amounts of both mutated and wt Elovl4 mRNAs. All these
data suggest that the STGD3-mediated pathophysiology in-
volves steps that are downstream of Elovl4 mRNA expres-
sion.
STGD3, similar to Stargardt disease-1 and age-related
macular degeneration, is characterized by accumulation of li-
pofuscin in the retinal pigmented epithelium [5,6]. Its main
fluorescent component is N-retinylidene-N-retinyletanolamine
(A2E), a cytotoxic product of condensation of phosphatidyle-
thanolamine with all-trans-retinaldehyde [28,29]. Also present
are the A2E precursors: dihydro-N-retinylidene-N-
retinylphosphatidylethanolamine (A2PE-H2), and N-
retinylidene-N-retinylphosphatidylethanolamine (A2PE) [23].
In vivo, these precursors are slowly converted into A2E, re-
sulting in A2E accumulation in retinal pigmented epithelium
[23]. All these compounds were found in the eyecups of 9-
month-old heterozygous Stgd3 mice. While the levels of A2E
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Figure 2. Southern blot verification of Stgd3 mouse genotype.  A: Genomic DNA was digested with NsiI and probed with a 5'-probe located
upstream of the recombinant targeted site (see Figure 1). A signal from the wt allele as well as an extra band (Rec), derived from the recombi-
nant allele, were detected in the Neo/wt DNA digests. The size of the Rec band was consistent with the 11.8-kb size predicted for the
homologous recombination event, confirming the presence of recombination in these mice. In the Stgd3/wt DNA digests, the size of the
recombined band was reduced due to loss of the Neo cassette with the result that the wt and Stgd3 allele-derived signals were not resolved. B:
Hybridization with the Neo probe detected the presence of the Neo signal in the Neo/wt but not in Stgd3/wt DNA digests, confirming
recombination of the targeting sequence and Cre-mediated excision of the Neo cassette, respectively. The Neo probe contained a mouse
phosphoglycerate kinase (PGK) promoter and thus also detected the endogenous PGK-gene sequence in all mouse DNA samples. C: Introduc-
tion of the STGD3 mutation into Elovl4 exon 6 generated a new Bpu10I restriction site in this exon. The presence of the STGD3-mutation in
the DNA of Neo/wt and Stgd3/wt mice was confirmed by the detection of a new 4.3-kb Bpu10I restriction fragment that was absent from wt/
wt DNA.
262were 13% higher in mutant eyecups compared to that in the
wt littermates, this difference was not sufficient to reach sta-
tistical significance (Table 1). In contrast, compared to the wt
littermates, the amounts of both A2E precursors were signifi-
cantly higher in the heterozygous Stgd3 mice, 87% more for
A2PE-H2 and 31% more for A2PE. These analyses are con-
sistent with the conclusion that our heterozygous Stgd3 mice
replicate the lipofuscin accumulation which is one of the early
hallmark features of the human STGD3 pathology [5,6].
Another feature of STGD3 is the juvenile-onset of visual
loss which in older patients may be accompanied by reduced
ERG signals [5,6]. Legal blindness occurs around a mean age
of 20 years but patients start to lose vision in their teenage
years [30]. We examined visual functions in our mutant mice
using ERG analysis. When compared to their wt littermates,
the 8-month-old heterozygous Stgd3 mice showed a reduc-
tion of their ERG responses to light, measured by the maxi-
mum rod b-wave amplitude and the maximum rod a-wave
amplitude expressed as the maximal amplitude of the rod com-
ponent (Figure 4, Table 2). The changes in the mutant cone-
derived component of the ERG, though trending lower, were
not statistically significant compared to that recorded in the
wt mice (Figure 4, Table 2). In summary, the heterozygous
Stgd3 mice reproduced two retinal features of the human dis-
ease: lipofuscin accumulation and reduced vision.
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Figure 3. Expression of Elovl4 and Stgd3
mRNAs in mouse eyecups.  S1-nuclease
protection assay, using a 322-nucleotide
(N) riboprobe, detected a 182-N fragment
protected by Elovl4 (wt) mRNA and two
fragments (126 Ns and 51 Ns) protected
by Stgd3 (mutant) mRNA. A: Elovl4
mRNA levels in wt/wt retinas remained
constant through the day/night cycle. B:
Stgd3/wt retinas from 1-month-old mice
expressed equivalent amounts of both wt
and Stgd3 mRNAs (ratio 1.02±0.06;
mean±SD, n=5). The level of Elovl4
mRNA in these mice was a half (51%±6;
mean±SD, n=4) of that detected in the
wt/wt littermates. RNA size standards in
a range of 100 N-500 N are shown. C:
The epidermal level of mutated Elovl4
mRNA (Stgd3 mRNA) in neonatal Stgd3/
Stgd3 mice is comparable to the Elovl4
mRNA levels in wt/wt and Stgd3/wt lit-
termates.
TABLE 1. LEVELS OF A2E AND ITS PRECURSORS IN EYECUPS OF 9-
MONTH-OLD WT/WT AND STGD3/WT MICE
Chloroform extracts from eyecups of individual mice were analyzed
for retinal fluorophores using high performance liquid chromatogra-
phy as described previously in reference [23]. Levels of A2E and its
precursors (A2E-H2 and A2PE) are expressed as means in pmoles
per eyecup±standard deviation. Six mice were analyzed per group.
263These changes were not, however, accompanied by reti-
nal degeneration. A light microscopy examination of retinal
sections from 8-month-old heterozygous Stgd3 mice revealed
no alterations in morphology when compared to the retinas of
wt littermates (Figure 5A). All layers of the retina were present
and no significant reduction in either the length of photore-
ceptor outer segments or the number of photoreceptor cell
bodies was noted at this age. Additional support for the un-
changed numbers of photoreceptors in 1-year-old Stgd3 mice
came from quantitative analysis of Elovl4 mRNA levels. To-
tal (combined wt and Stgd3) Elovl4 mRNA levels in heterozy-
gous Stgd3 retinas were the same as the wt Elovl4 mRNA
levels in wt retinas (ratio: 1.08±0.07, mean±SD, n=5).
Homozygous Stgd3 mice die after birth with symptoms of
a skin barrier defect:  Analysis of phenotypic changes in ho-
mozygous Stgd3 mice was limited because of their neonatal
lethality. Genotype analysis of 3-week-old progeny from ini-
tial breeding of heterozygous Stgd3 parents detected heterozy-
gous but no homozygous offspring. However, when progeny
were genotyped immediately following birth, pups with the
predicted Mendelian 1:2:1 genotype distribution were identi-
fied. Genotyping of newborn pups from 8 litters identified 15
wt/wt, 27 Stgd3/wt and 13 Stgd3/Stgd3 pups. Thus, homozy-
gous Stgd3 pups were born at the expected frequency but died
after birth. At birth, the homozygous Stgd3 neonates were in-
distinguishable from their littermates but shortly thereafter they
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Figure 4. Electroretinographic analysis of heterozygous Stgd3 mice.  Representative rod and cone electroretinograms, and a-wave responses
are presented for 8-month-old Stgd3/wt mice and their wt/wt littermates. Electroretinographic parameters obtained from all mice (n=6 per
group) examined for the study are summarized in Table 2.
TABLE 2. ELECTRORETINOGRAPHIC ANALYSIS OF 8-MONTH-OLD WT/WT
AND STGD3/WT MICE
     Variable          wt/wt     Stgd3/wt   Significance
-------------------   --------   --------   ------------
Rod amplitude (µV)     164±33     100±19      p<0.002
Cone amplitude (µV)     63±22      44±10      p<0.09
Rmp3 (µV)              134±21      85±20      p<0.003
S                       98±26     105±28      p<0.62
Electroretinographic parameters were derived from analysis of rod
and cone electroretinograms (representative electroretinograms see
Figure 4). Shown in this table are the values for rod amplitude ob-
tained using single blue flash (-0.5 log scot td/s) and for cone ampli-
tude obtained using single white flash on a rod-saturating background.
To calculate the maximal rod response (Rmp3) and the amplification
constant (S), the leading edge of the a-waves was fit as an ensemble
[53] using the Lamb and Pugh model [54] for the activation phase of
the phototransduction cascade. Values are means±standard deviation.
Six mice were analyzed per group.
264became lethargic and had erythematous, shiny and shriveled
skin. All homozygous Stgd3 pups died within 6-12 h after birth.
Photoreceptor defects could not be examined in homozy-
gous Stgd3 mice because retinal development is incomplete
in neonatal mice. While photoreceptor cell bodies are present
in neonate retina, they have not elaborated outer segments. In
homozygous Stgd3 retina, however, the outer retinal layer and
inner nuclear layer are present, displaying a normal morphol-
ogy comparable to that of wt neonatal retina (Figure 5B).
The skin phenotype observed in homozygous Stgd3 mice
is similar to that observed in knockout mice lacking
keratinocyte transglutaminase [31] or acyl-CoA:diacylglycerol
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Figure 5. Light micrographs of hematoxylin and eosin stained sections of Stgd3 mouse retinas.  A: Retinal sections from 8-month-old het-
erozygous Stgd3 mice and their wt littermates show similar thickness of photoreceptor outer segments (OS), inner segment (IS), outer nuclear
(ONL) and inner nuclear (INL) layers. No significant changes in numbers and morphology of photoreceptors are evident. Scale bar represents
10 µm. B: Retinal sections from neonatal homozygous Stgd3 mice and their wt littermates show similar retinal histology, with distinct INL and
larger outer retinal layers (ORL). The ORL contains the photoreceptor cell bodies which at this stage of development have not elaborated outer
segments. Scale bar represents 100 µm.
Figure 6. Defective skin barrier in neonatal homozygous Stgd3 mice.  A: Skin permeability assay. Euthanized neonatal pups were immersed in
a toluidine blue solution. The skin of homozygous Stgd3 mice, in contrast to their wt littermates, stained blue indicating a defect in skin barrier
function. B: Light microscopy examination of a cross section of the dye-stained skin of the homozygous Stgd3 neonate shows penetration of
the dye through the outer skin layers. C: Hematoxylin and eosin staining of homozygous Stgd3 skin shows the presence of all four epidermal
layers: stratum corneum (SC), stratum granulosum (SG), stratum spinosum (SP) and stratum basale (SB). Note the more compact structure of
stratum corneum in the mutant homozygous skin compared to the wt/wt and Stgd3/wt skin. Scale bar represents 100 µm in B.
265acyltransferase [26], both of which also die within a few hours
of birth with symptoms of a skin barrier defect. Using a skin
permeability assay [25], the homozygous Stgd3 mice also
showed a defect in skin barrier function. When the bodies of
euthanized neonatal mice were immersed in a toluidine blue
solution, the dye stained the skin of homozygous Stgd3 ani-
mals but not wt (Figure 6A) or heterozygous Stgd3 (not shown)
littermates. These findings suggest an underlying defect in the
epidermis of the homozygous Stgd3 mice. Histological analysis
of their skin showed that all four layers of the epidermis were
present (Figure 6C). In addition, the amount of mutated Elovl4
mRNA present in homozygous Stgd3 epidermis was compa-
rable to the amount of wt Elovl4 mRNA in wt epidermis (Fig-
ure 3C). This suggests no loss of Elovl4-expressing cells in
homozygous Stgd3 epidermis. Morphological alterations were,
however, evident in the outermost layer of the homozygous
Stgd3 epidermis, which appeared compacted and lacked the
laminations present in the wt and heterozygous Stgd3 epider-
mis. Alterations in the homozygous Stgd3 stratum corneum
offer a plausible explanation as to why toluidine blue can pen-
etrate and stain the inner epidermal layers (Figure 6B).
Homozygous Stgd3 mice lack skin acylceramides:  The
multiple lipid lamellae that are located in the extracellular
spaces between corneocytes in the stratum corneum are a vi-
tal component of the epidermal permeability barrier. These
lipid enriched membranes, elaborated as part of the natural
progression of differentiation of epidermal keratinocytes, are
composed of cholesterol (25% by weight), free fatty acids (10-
15%), and ceramides (45-50%) [32]. The epidermis is a very
active site of lipid biosynthesis and previous studies have
shown that inhibition of synthesis of the lipid components of
the lamellae leads to perturbations in barrier function [33].
The presence of the disrupted skin barrier function in homozy-
gous Stgd3 mice suggests that the lipid products of the Elovl4
enzymatic pathway may be important components of the lipid
fraction of the stratum corneum. To pursue this, we isolated
total unbound lipids from wt and homozygous Stgd3 neonatal
epidermis and analyzed their composition using HPLC/MS.
Both cholesterol and C16-C24 fatty acids, identified by
m/z values of MS analysis and by comparison to commer-
cially available standards, were detected in the lipid extracts
of wt and mutant epidermis (data not shown). However, when
the ceramide content of both extracts was compared, signifi-
cant differences were observed (Figure 7A). Mammalian epi-
dermis contains acylceramides and non-acylceramides [34-
36]. Non-acylceramides consist of sphingosine or hydroxy-
lated sphingosine linked to C18-C28 fatty acid. The
acylceramides are built of sphingosine or hydroxylated sph-
ingosine linked to an ω-hydroxy C30-C40 fatty acid which is
esterified by linoleic acid.
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Figure 7. Epidermal ceramides in neonatal homozygous Stgd3 mice.  Epidermal lipids were extracted and analyzed by high performance
liquid chromatography/mass spectrometry (HPLC/MS). Full scan MS analysis of an HPLC ceramide fraction detected non-acylceramides
(600-700 m/z) in both wt/wt (A) and Stgd3/Stgd3 epidermal extracts (B), but acylceramides (1000-1100 m/z) only in the wt/wt extract. Among
non-acylceramides, we identified C24-NS ceramide based on a comparison with a commercial C24-NS standard (isotopic mass=649.63). M/
z values for both were identical; 648.5 m/z in negative ion mode due to proton loss, and 632.4 m/z in positive ion mode due to proton gain and
water loss. Also detected in both extracts were its CH2-homologs: C25-NS ceramide (662.5 and 646.4 m/z in negative and positive mode,
respectively) and C26-NS ceramide (676.5 and 660.3 m/z, respectively). Among acylceramides in the wt/wt extract, we identified C34:1-EOS
ceramide (isotopic mass 1066.00) based on an m/z value of 1064.8 in negative mode due to proton loss, and 1048.9 m/z in positive mode due
to proton gain and water loss. Identity was further confirmed by fragmentation analysis (see Figure 9). Also present were CH2-homologs of
C34-EOS containing varying degrees of fatty acid saturation (see Figure 8). C shows the structures of an acylceramide with a C34-fatty acid
(C34:1-EOS) and a non-acylceramide with a C24 fatty acid (C-24-NS).
266MS analysis detected non-acylceramides in both wt and
homozygous Stgd3 lipid extracts, but acylceramides only in
the wt extracts (Figure 7). The molecular identities of non-
acylceramides were deduced using their m/z values in nega-
tive and positive ion mode of MS analysis and by comparison
to a commercially available C24-NS ceramide standard, con-
taining a C24 non-hydroxy fatty acid which is amide-linked
to sphingosine (see chemical structure in Figure 7C). In nega-
tive ion mode, the C24-NS standard (isotopic mass of 649.63)
produced a peak at 648.5 m/z, which in positive mode was
changed to 632.4 m/z as a consequence of water loss (-18)
and gain of two protons (+2). Peaks of identical m/z values in
both MS ion modes were observed for the wt and homozy-
gous Stgd3 lipid extracts (Figure 7) providing evidence for
the presence of C24-NS ceramide in both wt and mutant epi-
dermis. Also detected in both extracts were its CH2-homologs
as well as members of other classes of non-acylceramides that
contain hydroxylated sphingosine and/or a varying chain-
length fatty acid. Thus, based on MS analysis, all non-
acylceramides identified in the wt epidermal non-bound lip-
ids were also present in the homozygous Stgd3 epidermis.
In contrast to the non-acylceramides, MS analysis revealed
that all acylceramides were completely missing from the un-
bound lipid fraction of the homozygous Stgd3 epidermis. All
acylceramides contain an unusually long chain C30-C40 fatty
acid with an ω-hydroxy group esterified by linoleic acid
[32,36]. No commercial standards were available to aid in iden-
tification of these species. Therefore, acylceramides were iden-
tified based on their m/z values, water loss by sphingosine
ceramides in positive mode, and MS fragmentation analysis.
The 1066.37 m/z peak of the negative mode MS was identi-
fied as C34:1-EOS ceramide (isotopic mass of 1066.00) which
is composed of sphingosine linked to an ω-hydroxy
monounsaturated C34 fatty acid esterified with linoleic acid
(see chemical structure in Figure 7C). This ceramide loses
water in positive mode MS to give a 1048.92 m/z signal (Fig-
ure 7A and Figure 8). This same C34:1-EOS ceramide, with
identical MS signature, has previously been reported for mouse
epidermis [37]. Our wt epidermal extracts also contain C32-
C37 EOS ceramides which are CH2-homologs of C34:1-EOS
(Figure 7A), as well as other acylceramides that contain fatty
acids with varying degrees of saturation (Figure 8).
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Figure 8. Acylceramides of wild-type mouse epidermis.  Extended print-out of the acylceramides detected using positive ion mode MS
analysis (Figure 7). It shows the 1066.37 m/z peak identified as C34:1-EOS by fragmentation analysis (see Figure 9) and the 1048.92 m/z peak
of its dehydrated derivative. Signals 1020.95, and 1034.96 m/z correspond to C32:1-EOS, and C33:1-EOS, respectively. These are CH2-
homologs of C34-EOS. Other peaks can be assigned as EOS ceramides containing varied degrees of fatty acid saturation or as minor acylceramide
species (EOH and EOP) that contain an additional hydroxy group.
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Figure 9. Fragmentation analysis of wild-type epidermal ceramide.  The MS positive mode 1066.4 m/z peak (see Figure 7A) was fragmented
by collision-induced dissociation and resulted in generation of 1048.1, 1030.6, 744.2, and 769.0 m/z daughter ions. Chemical structures for
compounds of these molecular masses are provided in panel A: Further fragmentation of the 1030 m/z ion produced 1012.9, 768.6, 750.7, and
263.9 m/z signals (deduced compound formulas are shown in panel B). Transformation of the 768.6 m/z ion yielded 750.5 + 708.7 + 570.3 +
444.3 + 263.9 m/z ions (C), and fragmentation of the 750.5 m/z ion produced 571.1 and 506.2 m/z ions (D). The observed daughter ions are
consistent with fragment compounds expected from C34:1-EOS ceramide which contains sphingosine linked to an ω-hydroxy C34
monounsaturated fatty acid that is esterified with linoleic acid.
268Identification of the high molecular weight C34:1-EOS
ceramide was further confirmed by performing MS analysis
in positive ion mode on a successive series of fragmentation
products derived from collision induced dissociation of the
parent ion (Figure 9). Resulting daughter ions from fragmen-
tation analysis were consistent with identification of the par-
ent compound as a C34:1-EOS ceramide. The MS data, in
summary, indicate that the epidermis in homozygous Stgd3
animals is completely lacking in acylceramides.
DISCUSSION
 To study the physiological and pathophysiological functions
of Elovl4, we have generated Stgd3-gene knockin mice. They
are a genetic model of human STGD3 which is caused by
mutations in the human ELOVL4 gene. The Elovl4 targeting
construct was designed to not only introduce the human dis-
ease-associated 5-bp deletion but also to replicate exactly the
human amino acid C-terminal sequence coded by the human
pathogenic ELOVL4 allele.
Heterozygous Stgd3 mice were found to have alterations
that replicate both biochemical and functional features of the
human pathology. The eyes of 9-month-old heterozygous Stgd3
mice, while not showing statistically significant changes in
retinal A2E levels, did have increased levels of the A2E pre-
cursors, A2PE-H2 and A2PE. Recent studies have shown that
these precursors are slowly converted in vivo into A2E in wt
mice after intravitreal administration of A2PE-H2 [23]. Since
A2E and its precursors are major fluorescent constituents of
lipofuscin, this suggests that heterozygous Stgd3 mice repli-
cate STGD3-associated retinal lipofuscin accumulation, and
that they may represent a model of the early steps of this pro-
cess. Previously, increased A2E levels have also been shown
in transgenic mice over-expressing a human STGD3 protein
[19] as well as in abca4-gene knockout mice [28,29], an ani-
mal model of the phenotypically similar Stargardt disease-1.
A2E has been shown to be cytotoxic to retinal pigmented epi-
thelial cells [38-40] and, when present, may play a role in the
pathogenesis of macular degenerations, including age-related
macular degeneration [41].
Heterozygous Stgd3 mice also showed defects in visual
function, again replicating visual function alterations in
STGD3 patients [5,6]. The decrease in rod b-wave amplitudes
recorded in our mutant mice is similar to a decrease reported
for transgenic mice that over-express human STGD3 protein
in photoreceptors [19]. Although the heterozygous Stgd3 mice
exhibit biochemical and functional changes in the retina, we
do not see any significant morphological changes in the eyes
of 8-month-old animals using light microscopy. Ongoing stud-
ies will determine whether morphological changes will be
observed in much older animals. However, the lack of mor-
phological change in our 8-month-old mutants agrees with the
observation that heterozygous Elovl4 gene-knockout mice had
only minimal morphological abnormalities at the age of 17 to
19 months [20]. This lack of change, observed in both our
Stgd3 mice and in the Elovl4 gene-knockout mice, contrasts
with the progressive, although limited, morphological changes
reported in the retinas of another Elovl4 5 bp-deletion knock-
in mouse model [21]. This difference between the two Elovl4-
gene knockin mouse models is probably a result of several
differences that exist between the two models.
Compared to the mice generated by Vassireddy et al. [21],
our Stgd3 mice carry, besides the common 5-bp deletion, two
additional point mutations to generate the STGD3 protein C-
terminus. As a result the C-termini of both mutated Elovl4
proteins are different. Additionally, there are also other differ-
ences between these two mouse models. First of all, we in-
serted loxP in intron 5 of our Stgd3 mouse allele (Figure 1),
with the result that the loxP sequence is not incorporated into
the mutant Elovl4 mRNA. In contrast, the Vassireddy’s mouse
model was generated using a targeting vector which contained
a loxP-flanked Neo-cassette inserted in exon 6. After Cre-
mediated deletion of the Neo-cassette, this would result in the
presence of one loxP sequence in exon 6 and, therefore, in the
resulting mutant Elovl4 mRNA [21]. The presence of this ad-
ditional 34-nucleotide sequence, consisting of two 13-bp in-
verted repeats [42], may explain the different levels of mutant
Elovl4 mRNAs detected in both mouse groups. Vassireddy et
al. [21] found a reduction by approximately a half of the lev-
els of mutant Elovl4 mRNA compared to the wt Elovl4 mRNA
in retinas of heterozygous mutant mice. In contrast, in our
heterozygous Stgd3 mice the retinal levels of the mutant and
wt Elovl4 mRNAs were the same (Figure 3B). Beside the
above mentioned differences in nucleotide sequences and sta-
bility of mutant Elovl4 mRNAs, both mouse models are on
different genetic backgrounds.
To investigate the biochemical effects of the mutant al-
lele in our Elovl4 5 bp-deletion knock-in mouse model, we
initially examined the effects on Elovl4 mRNA levels. Using
a quantitative nuclease protection assay, we showed that ex-
pression of mRNA from the mutant Stgd3 allele in heterozy-
gous Stgd3 retinas does not lead to any up-regulation of ex-
pression from the wt Elovl4 allele. In fact, the mRNAs de-
rived from both, the Stgd3 and wt alleles, were present at the
same levels. There is, thus, no regulatory mechanism that de-
tects and/or compensate at the Elovl4 mRNA level for the pres-
ence of the pathogenic Stgd3 allele. Therefore, the pathogen-
esis involves a downstream pathway, most likely causing a
deficit of Elovl4 protein and/or its products.
This conclusion is supported by the findings that all three
different STGD3-associated mutations identified in the
ELOVL4 gene lead to protein truncation, with resulting loss
of an ER retention signal [1]. Previous studies have shown
that the human mutated ELOVL4 protein, when expressed in
transfected cultured cells, bound to co-expressed human wt
ELOVL4 protein and carried it from the ER [16-18], the site
of fatty acid synthesis. The result of this dominant negative
effect is a loss of the ER-located ELOVL4 protein. Additional
possible outcomes of an abnormal ELOVL4 subcellular lo-
calization may be deficiency of ELOVL4 lipid products and/
or a reduction in the wt and mutant ELOVL4 protein levels.
Further support for the dominant negative effect of the
STGD3 mutation and resulting Elovl4 enzyme deficiency is
suggested by the recently published studies in heterozygous
Elovl4 gene-knockout mice. Compared to their wt littermates,
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269these mice had no remarkable changes in ERG [20]. This is in
contrast to the reduced ERG signals in the heterozygous Stgd3
mice we report. One explanation for the ERG difference may
be increased ER deficiency of Elovl4 protein in heterozygous
Stgd3 mice as a result of its cellular miss-localization in the
presence of the mutated Elovl4 protein [16-18].
Since the ER is the site of synthesis of very long chain
fatty acids, an end-result of loss of ELOVL4 from there would
be deficiency of the ELOVL4 enzymatic products, especially
given that the elongation step is assumed to be the rate-limit-
ing step in synthesis of long chain fatty acids [7]. That the
fatty acid products of the Elovl4 gene are important cellular
constituents was suggested by the neonatal lethality observed
in our homozygous Stgd3 mice and the recently reported in-
ability to obtain homozygous Elovl4-gene knockout mice [20].
The most obvious change in the new-born homozygous Stgd3
mice was loss of skin barrier function. Whether a similar de-
fect in skin function would be present in humans homozygous
for the STGD3 mutation is unknown since we are not aware
of any reported progeny from parents who are both heterozy-
gous for the STGD3 mutation.
However, a similar skin phenotype has previously been
described for mice with aberrant skin lipid metabolism caused
by deletion of acyl-CoA:diacylglycerol acyltransferase-2 [26],
fatty acid transport protein-4 [43], or ARNT-transcription fac-
tor [37], and for mice lacking keratinocyte transglutaminase
which cross-links keratinocyte proteins producing insoluble
membranous structures in the stratum corneum [31]. Muta-
tions in keratinocyte transglutaminase have been found in some
families with the autosomal recessive skin disorder termed
lamellar ichtyosis [44-46]. Similar human skin pathologies may
also involve ELOVL4. This conclusion is supported by obser-
vation that atopic dermatitis results from defective skin bar-
rier function caused by significantly reduced levels of
acylceramides [47] which are completely absent from the epi-
dermis of our homozygous Stgd3 mice.
Epidermal keratinocytes synthesize acylceramide and
non-acylceramide lipids [33]. Because homozygous Stgd3
mouse epidermis contains non-acylceramides, all four
keratinocyte layers and high levels of mutated Elovl4 mRNA,
we conclude that the Elovl4-expressing cells are still present
in homozygous Stgd3 mouse epidermis and that the lack of
acylceramides is a direct result of the STGD3 mutation in the
Elovl4 protein. The compound acylceramide lipids, therefore,
emerge as, previously unknown, products of the Elovl4 bio-
synthetic pathway. Deficit of these lipids in homozygous Stgd3
mice is most probably caused by a lack of one of their biosyn-
thetic components. Homozygous Stgd3 epidermis was found
to have a normal complement of non-acylceramide lipids, lip-
ids which share ceramide backbones and in some cases li-
noleic acid in common with acylceramides. This suggests that
it is absence of another acylceramide component that leads to
their complete absence in homozygous Stgd3 mouse skin.
Unique to acylceramides, as compared to non-acylceramides,
and present in all classes of acylceramides, are very long chain
fatty acids containing 30-40 carbon atoms. Our studies sug-
gest that these fatty acids are the direct elongation products of
Elovl4. Till now, no elongase has been shown to have a role in
synthesis of such fatty acids. An inability to synthesize these
long chain fatty acids would explain the complete absence of
acylceramides from the lipid fraction of homozygous Stgd3
epidermis.
Acylceramide lipids are not found in the eye. However,
other compound lipids containing very long chain C30-C40
fatty acids have been detected in the retina [12,13,48], brain
[49] and testis [50], all tissues expressing high levels of Elovl4
mRNA [3,51]. In bovine retina such long chain fatty acids
have been found in dipolyunsaturated phosphatidylcholines
(PC) which also contain DHA at the sn-2 position [12]. These
particular PC species have been shown to maintain a tight as-
sociation with rhodopsin [52]. Ongoing studies will address
whether these PC species are altered in STGD3 retinas.
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